top of page


EVOQ Therapeutics is pioneering the development of a proprietary technology that represents a genuine breakthrough for autoimmune disease therapy.

Autoimmune Disease Vaccines

EVOQ's technology has demonstrated breakthrough efficacy in the gold-standard preclinical models of Multiple Sclerosis (MS) and Type-1 Diabetes (T1D). Success with these preclinical models  is considered proof of concept for the potential utility of our therapy in a wide range of autoimmune diseases.

With prevalence on the rise, autoimmune diseases have a devastating impact on the lives of 23.5 million Americans, and millions more children and adults around the world.

Examples of diseases EVOQ is investigating include:

  • Type 1 Diabetes

  • Celiac disease

  • Multiple sclerosis

  • Neuromyelitis Optica

  • MOG Antibody Disease

  • Rheumatoid arthritis

  • Primary Biliary Cholangitis

  • Systemic Lupus Erythematosus

  • Myasthenia gravis

  • Pemphigus

  • Graves' disease


EVOQ's technology utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens to dendritic cells residing in lymph nodes.

bottom of page